Published date: 5/23/2026

Value Proposition: Hydrogel platform that enables scalable production of cardiomyocytes

Technology Description

Researchers at Washington University in St. Louis have developed a chemically defined, tunable hydrogel platform that improves the production of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). While hiPSC-CMs provide a unique opportunity to recapitulate human cellular disease phenotypes, they have high user-dependence and poor reproducibility.

Preliminary method optimization within the platform has been conducted where an optimal hydrogel composition (bottom left, in contrast to a different composition in top left) can consistently increase mature hiPSCs, which results in structurally mature cardiomyocytes as shown via striated desmin and alpha-sarcomeric actin organization (right).

Publications

Available on request

Applications

• Disease modeling

• Drug screening

• Regenerative medicine

• 3D Bioprinting

Key Advantages

• Improved differentiation efficiency and structural and functional maturation

• Lowered variability compared to conventional 2D or suspension methods

• Can produce high cell counts

Patents
Patent application filed

Related Web Links – Nathaniel Huebsch Profile & Lab